GILEAD SCIENCES$51.58
-0.29
| Last Trade: |
51.58 |
| Trade Time: |
May 16 4:42 PM Eastern Daylight Time |
| Change: |
-0.29 (-0.56 %) |
| Prev Close: |
51.87 |
| Open: |
51.85 |
| Bid: |
51.45 |
| Ask: |
51.57 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
5/2/2012
|
Alton Gregg H
|
EVP, Corp & Med Affairs
|
-4,000
|
$52.00
|
-8.88%
|
|
5/2/2012
|
Alton Gregg H
|
EVP, Corp & Med Affairs
|
4,000
|
$19.36
|
9.74%
|
|
5/1/2012
|
Alton Gregg H
|
EVP, Corp & Med Affairs
|
-8,000
|
$51.69
|
-16.31%
|
|
5/1/2012
|
Alton Gregg H
|
EVP, Corp & Med Affairs
|
7,000
|
$19.36
|
16.64%
|
|
5/1/2012
|
MARTIN JOHN C
|
Chairman and CEO
|
-145,450
|
$51.71
|
-6.81%
|
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (GILD), click here.
-
The long-term appeal of Hanesbrands' business is still there, provided management delivers on its promise to reduce debt.
Read More »
-
Bullish magazine headlines have been the death of many a rising market, and in fact a correction is expected, says MoneyShow senior editor Tom Aspray, who points out a few sectors that look technicall ...
Read More »
-
Strong pipelines for the biotech sector as well as a wave of merger activity, have investors flocking to the stocks.
Read More »
-
These three stocks have posted big gains this year, but a proven technical measure shows all are trading at levels where chasing them is especially risky and not advised.
Even the renewed concerns ...
Read More »
-
Following bullish earnings, Karee Venema of Schaeffer’s Research writes that call buyers are piling in to one biopharmaceutical stock that has soared to three-year highs in just the last 60 days ...
Read More »
-
Bristol-Myers recently bought Inhibitex, a company leading the way in developing a treatment for Hepatitis C.
Read More »
Free Reports
|
|
